Denali Advisors LLC Purchases 29,700 Shares of Harmony Biosciences Holdings, Inc. $HRMY

Posted by on Aug 20th, 2026

Denali Advisors LLC boosted its position in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY – Free Report) by 49.6% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 89,600 shares of the company’s stock after acquiring an additional 29,700 shares during the period. Denali Advisors LLC owned 0.15% of Harmony Biosciences worth $3,262,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. BlackRock Inc. acquired a new stake in shares of Harmony Biosciences in the second quarter valued at about $258,583,000. SG Americas Securities LLC lifted its position in shares of Harmony Biosciences by 109.9% during the 1st quarter. SG Americas Securities LLC now owns 2,018,174 shares of the company’s stock worth $56,529,000 after purchasing an additional 1,056,507 shares during the last quarter. Armistice Capital LLC acquired a new position in shares of Harmony Biosciences during the 4th quarter worth about $18,710,000. AQR Capital Management LLC boosted its stake in Harmony Biosciences by 128.9% during the 4th quarter. AQR Capital Management LLC now owns 813,889 shares of the company’s stock valued at $30,456,000 after purchasing an additional 458,321 shares during the period. Finally, Arrowstreet Capital Limited Partnership boosted its stake in Harmony Biosciences by 42.8% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 1,295,381 shares of the company’s stock valued at $35,701,000 after purchasing an additional 388,472 shares during the period. Institutional investors and hedge funds own 86.23% of the company’s stock.

Harmony Biosciences Trading Up 2.8%

Shares of HRMY opened at $39.93 on Thursday. The stock’s 50-day moving average price is $36.19 and its 200 day moving average price is $32.71. The company has a quick ratio of 3.45, a current ratio of 3.48 and a debt-to-equity ratio of 0.13. The firm has a market capitalization of $2.33 billion, a price-to-earnings ratio of 12.96, a P/E/G ratio of 0.36 and a beta of 0.96. Harmony Biosciences Holdings, Inc. has a 12-month low of $25.52 and a 12-month high of $40.87.

Harmony Biosciences (NASDAQ:HRMY – Get Free Report) last announced its quarterly earnings data on Tuesday, August 4th. The company reported $1.28 EPS for the quarter, topping analysts’ consensus estimates of $0.96 by $0.32. The company had revenue of $261.28 million during the quarter, compared to the consensus estimate of $250.77 million. Harmony Biosciences had a return on equity of 20.06% and a net margin of 18.88%.The company’s quarterly revenue was up 30.3% on a year-over-year basis. During the same quarter last year, the company earned $0.92 EPS. As a group, research analysts predict that Harmony Biosciences Holdings, Inc. will post 3.77 earnings per share for the current year.

Wall Street Analyst Weigh In

Several brokerages have commented on HRMY. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and issued a $39.00 price target on shares of Harmony Biosciences in a research report on Wednesday, August 5th. Truist Financial increased their price objective on Harmony Biosciences from $29.00 to $34.00 and gave the company a “hold” rating in a research report on Wednesday, August 5th. Zacks Research lowered shares of Harmony Biosciences from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 11th. Needham & Company LLC upped their target price on shares of Harmony Biosciences from $45.00 to $50.00 and gave the company a “buy” rating in a research note on Tuesday, August 4th. Finally, HC Wainwright reissued a “buy” rating and issued a $55.00 price target on shares of Harmony Biosciences in a report on Thursday, July 16th. Four investment analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $45.50.

Check Out Our Latest Report on Harmony Biosciences

Harmony Biosciences Company Profile

(Free Report)

Harmony Biosciences Holdings, Inc is a commercial‐stage biopharmaceutical company focused on developing and delivering therapies for people with rare neurological and endocrine diseases. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, Harmony Biosciences went public in 2020 and trades on the Nasdaq under the ticker HRMY. The company’s mission centers on identifying and advancing medicines that address critical unmet needs in patient populations underserved by existing treatments.

The company’s flagship product is WAKIX (pitolisant), the first and only histamine H3 receptor antagonist/inverse agonist approved by the U.S.

Featured Articles

Institutional Ownership by Quarter for Harmony Biosciences (NASDAQ:HRMY)

Receive News & Ratings for Harmony Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harmony Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.